WDB coco Co., Ltd. (JP:7079)
:7079
Top Page
WDB coco Co., Ltd.
(7079)
Select Model
Select Model
Rating:73Outperform
Price Target:
¥3,027.00
▲(11.74% Upside)
Action:ReiteratedDate:10/23/25
The overall stock score of 73 for WDB coco Co., Ltd. is primarily driven by strong financial performance, with impressive revenue growth, profitability, and a robust balance sheet. A favorable valuation with a low P/E ratio and solid dividend yield further supports the score. However, weaker technical indicators reflecting a bearish trend temper the overall outlook, suggesting caution for short-term price momentum.
Positive Factors
Revenue Growth
The consistent revenue growth indicates strong market demand and effective business strategies, enhancing long-term market position.
Negative Factors
Earnings Per Share Decline
Declining EPS may indicate challenges in profitability or increased share dilution, potentially impacting investor confidence and stock performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The consistent revenue growth indicates strong market demand and effective business strategies, enhancing long-term market position.
Read all positive factors
WDB coco Co., Ltd. (7079) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.31B
Dividend Yield3%
Average Volume (3M)4.28K
Price to Earnings (P/E)9.1
Beta (1Y)0.62
Revenue Growth2.21%
EPS Growth-22.75%
CountryJP
Employees504
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)74.16
Shares Outstanding2,405,000
10 Day Avg. Volume5,990
30 Day Avg. Volume4,283
Financial Highlights & Ratios
PEG Ratio1.46
Price to Book (P/B)1.97
Price to Sales (P/S)1.59
P/FCF Ratio7.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)457.4
Revenue Forecast (FY)¥6.10B
WDB coco Co., Ltd. Business Overview & Revenue Model
Company Description
WDB coco Co., Ltd. provides contract services to pharmaceutical companies in Japan. The company supports the development of pharmaceuticals and medical devices with a focus on safety information management; safety information management support; c...
How the Company Makes Money
WDB Coco Co., Ltd. generates revenue through multiple streams, primarily from the sale of its cocoa and chocolate products. The company’s revenue model includes direct sales to food manufacturers and distributors, as well as retail sales through v...
WDB coco Co., Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.30B | 5.33B | 4.60B | 4.07B | 3.62B | 2.57B |
| Gross Profit | 1.98B | 2.07B | 1.93B | 1.58B | 1.44B | 900.88M |
| EBITDA | 1.26B | 1.36B | 1.31B | 1.12B | 981.71M | 536.06M |
| Net Income | 835.70M | 912.90M | 857.83M | 743.63M | 647.70M | 373.18M |
Balance Sheet | ||||||
| Total Assets | 5.27B | 5.60B | 4.67B | 3.67B | 3.14B | 2.14B |
| Cash, Cash Equivalents and Short-Term Investments | 3.39B | 3.48B | 2.66B | 2.00B | 1.89B | 1.28B |
| Total Debt | 15.22M | 29.81M | 27.12M | 24.32M | 33.52M | 19.97M |
| Total Liabilities | 1.01B | 1.30B | 1.10B | 866.02M | 994.57M | 568.81M |
| Stockholders Equity | 4.27B | 4.30B | 3.56B | 2.80B | 2.15B | 1.57B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.10B | 753.84M | 469.46M | 719.72M | 291.89M |
| Operating Cash Flow | 0.00 | 1.10B | 772.20M | 517.49M | 747.90M | 293.93M |
| Investing Cash Flow | 0.00 | -88.33M | -91.82M | -302.97M | -60.48M | -1.92M |
| Financing Cash Flow | 0.00 | -195.83M | -110.94M | -101.21M | -79.11M | -42.87M |
WDB coco Co., Ltd. Technical Analysis
Positive
2709.00
Price Trends
2618.59
Positive
2595.11
Positive
2655.45
Negative
Market Momentum
4.62
Negative
54.73
Neutral
50.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7079, the sentiment is Positive. The current price of 2709 is above the 20-day moving average (MA) of 2592.10, above the 50-day MA of 2618.59, and above the 200-day MA of 2655.45, indicating a neutral trend. The MACD of 4.62 indicates Negative momentum. The RSI at 54.73 is Neutral, neither overbought nor oversold. The STOCH value of 50.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7079.
WDB coco Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥6.31B | 9.13 | ― | 3.00% | 2.21% | -22.75% | |
64 Neutral | ¥6.20B | 11.64 | ― | 3.21% | 4.25% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥6.05B | -6.80 | ― | ― | 56.17% | -11.63% | |
43 Neutral | ¥5.83B | -0.95 | ― | ― | -50.27% | -3.33% | |
42 Neutral | ¥4.99B | -10.38 | ― | ― | -52.41% | -80.31% | |
41 Neutral | ¥4.99B | -2.01 | ― | ― | ― | 47.43% |
* Healthcare Sector Average
JP:7079
WDB coco Co., Ltd.
2,622.00
-486.82
-15.66%
JP:4539
Nippon Chemiphar Co., Ltd.
1,718.00
280.87
19.54%
JP:4582
Symbio Pharmaceuticals Limited
98.00
-52.00
-34.67%
JP:4586
Medrx Co., Ltd.
84.00
19.00
29.23%
JP:4883
Modalis Therapeutics Corporation
54.00
-23.00
-29.87%
JP:4892
Cyfuse Biomedical K.K.
607.00
-388.00
-38.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.